Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
184M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
41.4K
-
Shares change
-
0
-
Total reported value, excl. options
-
$70.3K
-
Price
-
$1.70
Significant Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) as of Q4 2023
1 filings reported holding HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock as of Q4 2023.
HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.4K shares
of 184M outstanding shares and own 0.02% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (26.7M shares), VANGUARD GROUP INC (8.34M shares), BlackRock Inc. (7.16M shares), Velan Capital Investment Management LP (6.99M shares), FRANKLIN RESOURCES INC (6.4M shares), Clearline Capital LP (6.07M shares), ORBIMED ADVISORS LLC (5.93M shares), Tejara Capital Ltd (5.28M shares), PALISADE CAPITAL MANAGEMENT, LP (3.65M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (2.91M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.